2,600 Shares in GeneDx Holdings Corp. $WGS Acquired by Strs Ohio

Strs Ohio purchased a new position in GeneDx Holdings Corp. (NASDAQ:WGS) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 2,600 shares of the company’s stock, valued at approximately $230,000.

A number of other hedge funds also recently modified their holdings of WGS. T. Rowe Price Investment Management Inc. bought a new stake in shares of GeneDx in the 1st quarter worth approximately $44,614,000. Alliancebernstein L.P. raised its holdings in shares of GeneDx by 3,054.5% in the 1st quarter. Alliancebernstein L.P. now owns 436,900 shares of the company’s stock worth $38,694,000 after purchasing an additional 423,050 shares during the period. Wellington Management Group LLP raised its holdings in shares of GeneDx by 202.3% in the 1st quarter. Wellington Management Group LLP now owns 425,647 shares of the company’s stock worth $37,697,000 after purchasing an additional 284,855 shares during the period. American Century Companies Inc. bought a new stake in shares of GeneDx in the 1st quarter worth approximately $23,877,000. Finally, Westfield Capital Management Co. LP bought a new stake in shares of GeneDx in the 1st quarter worth approximately $19,704,000. Institutional investors own 61.72% of the company’s stock.

Insider Activity

In other news, CFO Kevin Feeley sold 5,278 shares of the business’s stock in a transaction on Wednesday, July 9th. The shares were sold at an average price of $93.00, for a total transaction of $490,854.00. Following the completion of the transaction, the chief financial officer directly owned 3,392 shares in the company, valued at $315,456. The trade was a 60.88% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Katherine Stueland sold 10,501 shares of the company’s stock in a transaction on Tuesday, September 16th. The stock was sold at an average price of $121.47, for a total transaction of $1,275,556.47. Following the completion of the transaction, the chief executive officer owned 14,578 shares of the company’s stock, valued at $1,770,789.66. This trade represents a 41.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 575,870 shares of company stock valued at $69,280,301 over the last 90 days. Company insiders own 29.60% of the company’s stock.

Wall Street Analyst Weigh In

WGS has been the topic of a number of analyst reports. Guggenheim reissued a “buy” rating and set a $115.00 target price (up previously from $88.00) on shares of GeneDx in a report on Monday, June 30th. Piper Sandler boosted their target price on shares of GeneDx from $120.00 to $140.00 and gave the company an “overweight” rating in a report on Thursday, September 11th. Wells Fargo & Company boosted their target price on shares of GeneDx from $78.00 to $95.00 and gave the company an “equal weight” rating in a report on Wednesday, July 30th. Finally, Wall Street Zen raised shares of GeneDx from a “hold” rating to a “buy” rating in a report on Saturday, August 2nd. Six research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $104.13.

GeneDx Stock Down 6.0%

WGS opened at $114.22 on Thursday. The company has a fifty day moving average price of $114.04 and a 200-day moving average price of $93.37. The firm has a market capitalization of $3.28 billion, a P/E ratio of 2,284.40 and a beta of 2.04. The company has a debt-to-equity ratio of 0.19, a current ratio of 2.87 and a quick ratio of 2.70. GeneDx Holdings Corp. has a one year low of $35.88 and a one year high of $136.00.

GeneDx (NASDAQ:WGS) last released its quarterly earnings results on Tuesday, July 29th. The company reported $0.50 EPS for the quarter, beating analysts’ consensus estimates of $0.10 by $0.40. The firm had revenue of $102.69 million during the quarter, compared to analyst estimates of $86.00 million. GeneDx had a net margin of 0.39% and a return on equity of 16.51%. GeneDx has set its FY 2025 guidance at EPS. Equities research analysts expect that GeneDx Holdings Corp. will post 0.97 earnings per share for the current fiscal year.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.